Trends in medical care utilization in patients with cancer: An analysis of real-world data in a tertiary hospital in Korea, 2014–2019

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2023-10-30 DOI:10.1002/cam4.6660

Jung-Hyun Won, Tae Kyu Chung, Joochul Lee, Sangwon Yoon, Yoomin Jeon, Howard Lee

{"title":"Trends in medical care utilization in patients with cancer: An analysis of real-world data in a tertiary hospital in Korea, 2014–2019","authors":"Jung-Hyun Won, Tae Kyu Chung, Joochul Lee, Sangwon Yoon, Yoomin Jeon, Howard Lee","doi":"10.1002/cam4.6660","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Rising costs of cancer treatments challenge even areas with universal health coverage. There's a need to assess current medical care utilization trends among patients with cancer to guide public health policy, resource allocation, and set informed healthcare goals.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We analyzed the latest trends in medical care utilization by cancer patients in four areas—drugs, radiation therapy (RT), surgery, and diagnostic procedures—using clinical databases extracted from electronic medical records of a tertiary hospital in Korea between 2014 and 2019. Compound adjusted growth rates (CAGR) were computed to capture the annual growth over the study period.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 74,285 cancer patients were identified, with 40.3% (29,962), 14.2% (10,577), 31.1% (23,066), and 92.6% (68,849) of patients having received at least one anticancer agent, RT, surgery, and diagnostic procedure, respectively, over the period. We observed a 1.7-fold increase in the use of targeted · immune-oncology agents (from 6.8% to 11.6%) and a 21-fold increase (from 3.0% in 2014 to 65.7%) in intensity-modulated RT (IMRT) use over the period. In contrast, we observed a continuous decrease in the proportion of patients who underwent surgical treatment from 12.2% in 2014 to 10.9% in 2019. This decrease was particularly noticeable in patients with colon cancer (from 28.5% to 24.2%) and liver cancer (from 4.1% to 2.9%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>From 2014 to 2019, there was a significant rise in the use of targeted · immune-oncology agents and IMRT, alongside a decline in surgeries. While targeted · immune-oncology agents and IMRT may offer promising outcomes, their financial impact and potential for overuse necessitate careful oversight and long-term cost-effectiveness studies.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"12 22","pages":"21022-21031"},"PeriodicalIF":2.9000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.6660","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.6660","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Rising costs of cancer treatments challenge even areas with universal health coverage. There's a need to assess current medical care utilization trends among patients with cancer to guide public health policy, resource allocation, and set informed healthcare goals.

Methods

We analyzed the latest trends in medical care utilization by cancer patients in four areas—drugs, radiation therapy (RT), surgery, and diagnostic procedures—using clinical databases extracted from electronic medical records of a tertiary hospital in Korea between 2014 and 2019. Compound adjusted growth rates (CAGR) were computed to capture the annual growth over the study period.

Results

A total of 74,285 cancer patients were identified, with 40.3% (29,962), 14.2% (10,577), 31.1% (23,066), and 92.6% (68,849) of patients having received at least one anticancer agent, RT, surgery, and diagnostic procedure, respectively, over the period. We observed a 1.7-fold increase in the use of targeted · immune-oncology agents (from 6.8% to 11.6%) and a 21-fold increase (from 3.0% in 2014 to 65.7%) in intensity-modulated RT (IMRT) use over the period. In contrast, we observed a continuous decrease in the proportion of patients who underwent surgical treatment from 12.2% in 2014 to 10.9% in 2019. This decrease was particularly noticeable in patients with colon cancer (from 28.5% to 24.2%) and liver cancer (from 4.1% to 2.9%).

Conclusion

From 2014 to 2019, there was a significant rise in the use of targeted · immune-oncology agents and IMRT, alongside a decline in surgeries. While targeted · immune-oncology agents and IMRT may offer promising outcomes, their financial impact and potential for overuse necessitate careful oversight and long-term cost-effectiveness studies.

Abstract Image

查看原文本刊更多论文

癌症患者医疗保健利用趋势：2014-2019年韩国一家三级医院真实世界数据分析。

背景：癌症治疗费用的上涨甚至挑战了全民健康覆盖的地区。有必要评估癌症患者目前的医疗保健利用趋势，以指导公共卫生政策、资源分配和制定知情的医疗保健目标。方法：我们利用从2014年至2019年韩国一家三级医院的电子医疗记录中提取的临床数据库，分析了癌症患者在放疗、放射治疗（RT）、手术和诊断程序四个领域医疗保健利用的最新趋势。计算复合调整增长率（CAGR）以获取研究期间的年增长率。结果：共鉴定出74285名癌症患者，其中40.3%（29962）、14.2%（10577）、31.1%（23066）和92.6%（68849）的患者在此期间分别接受了至少一种抗癌药物、RT、手术和诊断程序。在此期间，我们观察到靶向免疫肿瘤药物的使用量增加了1.7倍（从6.8%增加到11.6%），强度调节RT（IMRT）的使用量也增加了21倍（从2014年的3.0%增加到65.7%）。相比之下，我们观察到接受手术治疗的患者比例从2014年的12.2%持续下降到2019年的10.9%。这一下降在癌症（从28.5%降至24.2%）和癌症（从4.1%降至2.9%）患者中尤为明显。结论：从2014年到2019年，靶向免疫肿瘤药物和IMRT的使用显著增加，同时手术减少。虽然靶向免疫肿瘤药物和IMRT可能会带来有希望的结果，但其财务影响和过度使用的可能性需要仔细监督和长期成本效益研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.